Novo Nordisk Shares Rise: Wegovy Obesity Pill Launch Success
Novo Nordisk stock Jumps on Promising Wegovy Pill Launch Data
shares of Novo Nordisk (NVO) increased by more then 8% on Friday, January 17, 2026, following positive early prescription data for its newly launched weight loss pill, Wegovy. The pill represents the first oral medication approved for chronic weight management.
TD Cowen analysts described the launch as a “solid start” in a note released Friday, but cautioned against drawing definitive conclusions from limited data.They emphasized the need for further data to accurately gauge sustained demand for Wegovy, which officially became available in the U.S. on January 5, 2026, after receiving FDA approval in late December 2025.
George Frey | Bloomberg | Getty Images